Ahmed Sherihan Rezk, Zeinhom Mohamed G, Ebied Ahmed Ahmed Mohamed Kamal, Kamel Islam Fathallah Mohamed, Almoataz Mohamed Ahmed, Daabis Ahmed Mohamed Ali, Akl Ahmed Zaki Omar, Mahmoud Emad Labib Abdelhamid, Alkhalefeh Adnan Ghazi, Ouf Shady G, Mosbah Suaad Abdallah Ali, Sirag Igbal Mubarak Ismail, Abouelnaga Mohamed, Khalil Mohamed Fouad Elsayed
Neurology Department, Faculty of Medicine, Kafr El-Sheikh University, Elgeish Street, Kafr El-Sheikh, Egypt.
Neurology Department, Faculty of Medicine, Zagazig University, 2 Elgeish Et, Zagazig, Egypt.
Sci Rep. 2025 May 5;15(1):15655. doi: 10.1038/s41598-025-97968-3.
Embolic stroke is connected to a higher risk of hemorrhagic transformation (HT), functional disability, and mortality. Although, AF and HT are not one entity; no such study evaluated the factors, including AF types and treatment, which could predict the different types of HT in AF patients presenting with embolic stroke and administered alteplase. We aimed to assess the predictors of HT in general and predictors of different ECASS-based subtypes of post-alteplase HT in AF patients who experienced first-ever embolic ischemic stroke. Our study included 716 AF patients who presented with acute embolic stroke and received the full recommended dose of alteplase. The study comprised six parallel groups. The first group consisted of 509 patients who did not experience haemorrhagic transformation. The second group comprised 207 patients who had any HT. The third group comprised 87 patients with haemorrhagic infarction (HI)1. The fourth group comprised 62 patients with HI2. The fifth group comprised 33 patients with parenchymal hematoma (PH) 1, and the sixth group comprised 25 patients with PH 2. We evaluated the ability of different baseline characters and risk factors to predict the occurrence of HT in general and the predictors of occurrence of different ECASS-based HT subtypes. HT was detected in 207 patients (28.9%), older age, higher NIHSS, sustained AF, warfarin use, and higher HAS-BLED score were independent predictors of all ECASS-based subtypes of hemorrhagic transformation; moreover, anterior-circulation stroke was an independent predictor of PH 1 and PH 2. In atrial fibrillation patients presented with first-ever embolic stroke and received alteplase in Egypt and the United Arab Emirates, older age, higher NIHSS, sustained AF, warfarin use, and higher HAS-BLED score were independent predictors of all ECASS-based subtypes of haemorrhagic infarction; in addition, anterior-circulation stroke was an independent predictor of PH 1 and PH 2.Trial registration (clinicaltrials.gov NCT06653946), retrospectively registered on 23/10/2024.
栓塞性中风与出血性转化(HT)、功能残疾和死亡率的较高风险相关。尽管房颤和HT并非同一回事;但尚无此类研究评估包括房颤类型和治疗在内的因素,这些因素可预测接受阿替普酶治疗的栓塞性中风房颤患者中不同类型的HT。我们旨在评估首次发生栓塞性缺血性中风的房颤患者中HT的总体预测因素以及基于欧洲急性卒中协作研究(ECASS)的阿替普酶治疗后HT不同亚型的预测因素。我们的研究纳入了716例出现急性栓塞性中风并接受了推荐全剂量阿替普酶治疗的房颤患者。该研究包括六个平行组。第一组由509例未发生出血性转化的患者组成。第二组包括207例发生任何HT的患者。第三组包括87例出血性梗死(HI)1患者。第四组包括62例HI2患者。第五组包括33例实质血肿(PH)1患者,第六组包括25例PH 2患者。我们评估了不同基线特征和危险因素预测总体HT发生的能力以及基于ECASS的不同HT亚型发生的预测因素。207例患者(28.9%)检测到HT,年龄较大、美国国立卫生研究院卒中量表(NIHSS)评分较高、持续性房颤、使用华法林以及较高的HAS - BLED评分是所有基于ECASS的出血性转化亚型的独立预测因素;此外,前循环中风是PH 1和PH 2的独立预测因素。在埃及和阿拉伯联合酋长国首次发生栓塞性中风并接受阿替普酶治疗的房颤患者中,年龄较大、NIHSS评分较高、持续性房颤、使用华法林以及较高的HAS - BLED评分是所有基于ECASS的出血性梗死亚型的独立预测因素;此外,前循环中风是PH 1和PH 2的独立预测因素。试验注册(clinicaltrials.gov NCT06653946),于2024年10月23日进行回顾性注册。